Correction to: Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors
Masuda K, Aoki K, Kamiko K, et al. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors. Expert Opin Pharmacother 2013;14(9):1111-8.
Following publication of this article, some errors have been identified in the text within the results section, legend of Figures 2 and 3. The errors occur within the first paragraph of Section 3.1 ‘Profile of the patients’ on page 1113. In three places the words ‘of acarbose’ was missing after dose quantities. Also, the number of patients receiving 0.3 mg/meal of voglibose in ‘Intake 1 group’ should have been ‘2’ and not ‘1’. Finally, in four places, ‘patient’ should have read ‘patients’. Please find the corrected paragraph below, with alterations shown in bold.
Of the 47 subjects enrolled in the study, 12 were assigned to the Intake 0 group, 12 to the Intake 1 group, 11 to the Intake 2 group and 12 to the Intake 3 group (Figure 1). No significant differences in the demographic or clinical parameters were observed among the 4 groups at the baseline (Table 1). Most patients received 25 mg of alogliptin. The number of patients given 12.5 mg alogliptin was 1 in the Intake 0 group, 1 in the Intake 1 group, 2 in the Intake 2 group and 1 in the Intake 3 group due to the renal function and 1 in the Intake 2 group due to the doctor’s judgment. The number of patients given 0.2 mg/meal of voglibose, 0.3 mg/meal of voglibose and 75 mg/meal of miglitol was 7, 2 and 1 in Intake 0 group, respectively. The number of patients given 0.2 mg/meal of voglibose, 0.3 mg/meal of voglibose, 100 mg/meal of acarbose and 50 mg/meal of miglitol was 6, 2, 2 and 1 in Intake 1 group, respectively. The number of patients given 0.2 mg/meal of voglibose, 0.3 mg/meal of voglibose, 100 mg/meal of acarbose and 50 mg/meal of miglitol was 6, 2, 2 and 1 in Intake 2 group, respectively. The number of patients given 0.2 mg/meal of voglibose, 0.3 mg/meal of voglibose, 100 mg/meal of acarbose and 50 mg/meal of miglitol was 3, 3, 3 and 1 in Intake 3 group, respectively.
The legend of Figures 2 and 3 contain some typographical errors. The correct version of the legend is given below, with alterations shown in bold.
Figure 2. Changes in the HbA1c values from the baseline at 1 and 3 month/s in the four groups. The data shown are the means ± SD.
*p < 0.01 vs baseline, ‡p < 0.05 vs intake 0 group (two-way repeated-measures ANOVA with post-hoc pairwise comparisons (Bonferroni’s correction)).
Figure 3. Changes in the Glycoalbumin (GA) values from the baseline at 1 and 3 months in the four groups. The data shown are the means ± SD.
*p < 0.05, § p < 0.001 vs baseline, ‡ p < 0.01 vs intake 0 group (two-way repeated-measures ANOVA with post-hoc pairwise comparisons (Bonferroni’s correction)).